Illumina, Inc. (NASDAQ:ILMN) had its target price raised by Argus from $205.00 to $235.00 in a report published on Wednesday morning. Argus currently has a buy rating on the life sciences company’s stock.

Several other equities analysts have also recently issued reports on ILMN. Vetr upgraded shares of Illumina from a buy rating to a strong-buy rating and set a $197.84 price target on the stock in a research report on Tuesday, June 27th. BidaskClub cut shares of Illumina from a hold rating to a sell rating in a research report on Thursday, August 17th. Zacks Investment Research cut shares of Illumina from a buy rating to a hold rating in a research report on Friday, August 4th. J P Morgan Chase & Co reiterated an overweight rating and set a $250.00 price target on shares of Illumina in a research report on Wednesday, August 2nd. Finally, First Analysis upgraded shares of Illumina from an underweight rating to an equal weight rating and set a $176.00 price target on the stock in a research report on Wednesday, August 2nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $181.76.

Illumina (NASDAQ:ILMN) traded down 0.6834% during trading on Wednesday, hitting $211.9710. 48,128 shares of the stock were exchanged. Illumina has a 52 week low of $119.37 and a 52 week high of $214.04. The stock has a market cap of $30.95 billion, a P/E ratio of 42.5303 and a beta of 0.81. The stock has a 50 day moving average of $194.72 and a 200-day moving average of $179.64.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the previous year, the company earned $0.86 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts expect that Illumina will post $3.65 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Price Target Increased to $235.00 by Analysts at Argus” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/illumina-inc-ilmn-price-target-increased-to-235-00-by-analysts-at-argus.html.

In related news, CAO Michel Bouchard sold 616 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,200.00. Following the transaction, the chief accounting officer now owns 15,161 shares in the company, valued at $3,032,200. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80. Following the transaction, the senior vice president now owns 10,646 shares in the company, valued at approximately $1,854,959.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 165,705 shares of company stock worth $31,202,418. 1.60% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC lifted its position in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 89 shares during the period. Penserra Capital Management LLC lifted its position in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after purchasing an additional 102 shares during the period. Paradigm Asset Management Co. LLC lifted its position in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the period. Patten Group Inc. lifted its position in Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. lifted its position in Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 100 shares during the period. Institutional investors own 93.34% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.